RyCarma Therapeutics

Biotechnology Research • • 1-10 Employees

Company overview

Headquarters	XX
Website	rycarma.com
NAICS	541714
Employees	1-10

Key Contact at RyCarma Therapeutics

Chloe Ibsen

Associate Director, Corporate Development & Strategy

About RyCarma Therapeutics

RyCarma is a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Our drug discovery platform is built from deep expertise on ryanodine receptors (RyRs), channels that regulate the intracellular flow of calcium ions in nearly all cell types. We hold an exclusive license from Columbia University for its RyR technology based on the research of our founder, Dr. Andrew Marks. RyCarma’s lead candidate, ARM210, is in development for the treatment of heart failure and ryanodine receptor 1-related myopathies (RYR1-RM).

RyCarma Therapeutics revenue & valuation

Annual revenue	$598,885
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,000,000
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Director

Partner

Employees by Department

RyCarma Therapeutics has 2 employees across 2 departments.

Departments

Number of employees

Funding Data

RyCarma Therapeutics has never raised funding before.

Frequently asked questions

RyCarma Therapeutics is located in XX.

RyCarma Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at RyCarma Therapeutics

Chloe Ibsen

Associate Director, Corporate Development & Strategy

4.8

40,000 users